Clinical Trials Browser

Phase 3 × Neoplasms × exemestane × Clear all

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Phase 3 Enrolling by invitation

Breast Neoplasms, Neoplasms